The use of radioactive iodine has become an important adjunct to the treatm ent ofthyroid cancer. Many normal tissues-including salivary glands, gastro intestinal mucosa, gonads, and lactating breast tissue-have the ability to conc entrate radioa ctive iodin e under normal circumstances. Although the mechani sm is just beginning to be elucidated, it is this ability that might contribute to the immediate and long-t erm complications associated with radioacti ve iodin e treatment. In some patients, the sali -VQlY complications can be perman ent and might compromise daily functionin g. In this article, we examin e the salivary gland complications associated with radioactiv e iodine therapy, and we suggestpotential protective mechanisms to circumvent these problems.
Introduction
Salivary glands serve a vital function in the maintenance of periodontal health , the preparation and delivery of nutrients to the alimentary tract , taste discrim ination, and speech. The mai n produc t of the salivary glands, saliva , plays an integral part in maintaining oral competency, both physiologically (throug h the presence of proteins such as amy lase, immunoglobulins, and lysozyme) and functionally (through lubrication of the oral mucosa). A loss or decrease of salivary flow or production can impair the ability to perfo rm these functions and is associated with increa sed morbidity. The ability to concentrate iodine and radioactive iodine makes the sali vary gland s potential target s during and after the use of these modalities.
In this article, we discuss the short -and long-term effects of radioactive iodine on salivary gland function. In addition, we discuss the potential role of modulating and cytoprotective agen ts, with emph asis on the prevention of salivary gland dysfunction .
Normal anatomy and physiology
Physiology ofsaliva. The major salivary gland s consist of three pairs of tissue: the parotid glands, the submandibular glands, and the sublingual glands. The minor salivary glands-which number betwe en 600 and I,OOO-line the oral and nasal mucosa and the upper digesti ve tract. Embryogenesis of the major and minor salivary gland s in the oral cavity begins with the deve lopment of the major ducts from ecto dermal tissue.I Sali vary gla nd development begins duri ng the .fourth week of gestation with the development of the parotid glands , followed by the developmen t of the submandibular glands at 6 weeks, the sublingual gla nds at 8 weeks, and the minor salivary glands at 3 mont hs. The mesenchyme is penetrated by proliferating buds that arbor ize and terminate in acini . The epithelial buds enlarge and the glands canalize before the completion of acini deve lopment.
In the oropharynx, normal physiologic function of the salivary glands involves: ( I) lubrication , (2) enhancement of digestion through enzymatic and mechanical manipulation, (3) production of hormones and other metabolically active compounds, (4) immunologic defen se, and (5) mediation of taste. The se glands are primarily under the control of the autonomic nervou s system. Parasympathetic stimulation appears to be the major contributor to saliva production, but symp athetic input also play s a role.'
The parotid glands recei ve their neural input primari ly from secretomotor fibers transmitted from the otic ganglion . Sympathetic nerve fiber s from the superior cerv ical ganglion, along with the postganglionic fibers of the parasympathetic nervous system, synapse with intercalated cells, myoepithelial cells, and acinar cells. After ,
PATIENT-DAYS OF THERAPY*
Salagen" Tablets provide patients with effective, well-tolerated therapy. The most common side effect is sweating, especially at higher doses. Salagen Tablets do not work for everyone, and are contraindicated when uncontrolled asthma is present and when miosis is undesirable. Please see next page for brief summary of prescribing information.
Inlong-term treatmentwere two pat ients with underlyingcardiovascular disease of whom one exper ienced a myocardial infarct and another an episode of syncope. The association with drug is uncertain. Sjogren'sSyndromePatients: Incontrolled studies,376patients received pilocarpi ne, of whom 5% were men and 95% were women. Race distribution was 84%Caucaaan, g%Oriental ,3%Black, and4%of other origin. Mean age was 55 years. The majority of pat ients were between 40 and 69 years (70%), 16%were 70 years and older and 14% were youngerthan40yearsof age.Ofthesepatients, 161 16 29(891376receiving pilocarpine)were over the age of 65 years.The adverse events reported bythoseover 65yearsandthose65yearsandyounger werecom parabl e except fornotabl etrends for urinaryfrequency,diarrhea,and dizziness.The incidences of urinary frequency and diarrheain theelder ly were about doublethose in the non-elderly.The incidence of dizziness wasabout three times ashi gh in the elderly as in the non-elderl y. These adverse exper iences were not considered to be serious. In the 2 placebocontrolled studies, the most com mon adverse events related to drug use weresweating, urinaryfrequency,chill s,andvasodilatation (flushing ).The mos t commonlyreportedreasonfor patient discontin uationof treatment was sweating. Expectedpharmacologic effects ofpilocarpineincludethe followingadverse experiences associated with SALAGEN' Tablets:
Pregnancy: Teratogenic eHects.
PregnancyCategoryC: Pilocarpine was associatedwith a reductionin the mean fetal body weight andan increase in the incidence of skeletal variations when given to pregnant rats at a dosage of 90 mgl kglday (approximately 26times the maximum recommended dose for a 50 kg human when compared on the basis of body surtace area (mglm') est imates). These effects may have beensecondary to maternal toxicity, In another study, oral administrationof pilocarpineto female rats duri ng gestation and lactation at a dosage of 36 mglkglday (approximately 10 times the maximum recommended dose for a 50 kg human when com pared on thebasis of body surtace area (mgl m1 est imates) resulted in anincreasedincidence of stillbi rths; decreasedneonatal survival and reduced mean body wei ght of pups were observed at dosages of 1B mglkgl day (approxi mately 5 times the maximumrecommendeddosefor a 50 kg human when compared on the basis of body surtace area (mglm1 estimates) and above. Therearenoadequateandwell-controlled studies in pregnant women. SALAGEN" Tablets should be used during pregnancy only if the potential benefit justifiesthepotential risk to the fetus.
Nursing Mothers: It is not known whether this drug is excreted in humanmilk. Becausemanydrugs areexcreted inhumanmilk and because of the potential for seriousadverse reactions in nursing infants from SALAGEN' Tablets, a decision should be made whet her to discontinue nursing or to discontinuethedrug, takinginto account theimportanceof thedrug to themother.
Pediatric Use: Saf etyand effectiveness in pediatric patients have not been established.
Geriatric Use: Head and Neck CancerPatient s: Intheplacebo-controlled clinical trial s (see Clinical Studiessection in full prescribinginformati on) themeanageof patients was appr oxi mately5Byears(range19to80). Of these patients, 971369 (611217 receiving pil ocarpine) were over the age of 65 years. In the healthy vol unteer studies,151150 SUbjects were over theage of 65years. In bot h study populations, theadverse events report ed by those over 65 years and those 65 years and younger were com parable. Ofthe 15 elder ly vol unteers (5 women, 10 men), the5 women had higher Cmax's andAUC's thanthemen.
Sjogren'sSyndrome Patients: Intheplacebo-controlledclinical trials, the mean age of patientswasapproximately 55years (range 21 to 85). The adverseevents reported by those over65years andthose 65years and younger werecomparable except for notabletrends for urinary frequency, diarrhea, and dizziness (see ADVERSEREA CTIONS section). 
ADVERSE REACTI ONS: Head

SALAGEN" Tablets
Ipilocarplne hydrochloride)
Brief Summary
Consult package insert for full prescribing infor mation INDICATIONS AND USAGE: SALAGEN" Tablets areindicated for 1) the treatment of symptomsof dry mout h fromsalivary gland hypofunction caused by radiotherapy for cancer of the head and neck; and 2) the treatmentofsymptomsof drymouth in patients withSjogren'ssyndrome.
CDNTRAINDICATIDNS: SALAGEN' Tablets are contraindicat ed inpatients with uncontrolled ast hma, known hypersensitivity to pilocarpin e, and when miosisisundesirable,e.g., inacute iritis and innarrow-angl e(angle closu re) glaucoma.
WARNINGS:
Cardiovascular Di sease: Patient s withsi gnificant cardi ovascular di sease may beunabletocompensatefortransientchanges inhemodynamicsor rhythminducedby pilocarpine. Pulmonary edema has beenreported asa complicationof pi locarpinetoxicity fromhi gh ocular doses givenforacute angle-closure glaucoma. Pi locarpineshould beadministered with caution in and under close medi cal supervision of patients with significant cardiovascul ar disease.
Ocular: Ocular formulationsof pil ocarpine have beenreportedto cause visualblurring whichmay resul t in decreased vi sual acuity, especially at night and in patient s with centr allenschanges,andto cause impairment of depthperception.Caution should be advised while drivi ngat nightor pertorminghazardousact ivitiesin reduced lighting.
Pulmonary Di sease: Pil ocarpine has been reportedto increase airway resistance, bronchial smooth muscle tone, and bronchial secretions. Pilocarpine hydrochloride should be administered with caution to and under close medical supervision in patient s with cont rolled asthma, chron ic bronchi tis, or chronic obstructive pulmonary di sease requiring pharm acoth erapy.
PRECAUTIONS:
General: Pil ocarpinetoxicity is character ized by an exaggeration of its parasympathomim eti c effects. These may include: headache, visual disturbance, lacrimation, sweating, respi ratory distress, gastrointestinal spasm, nausea, vomiting, diarrhea, atrioventricular block, tachycardia, bradycardia, hypotension, hypert ension,shock, mentalconfusi on, cardiac arrhyt hmia, and tremors.
The dose-rel ated cardiovascul ar pharmacologic effects of pilocarpine incl udehypotensi on, hypert ension,bradycardi a, and tachycardia.
Pil ocarpi neshouldbeadministered wi th caution to patient s with knownor suspected cholelithiasis or biliary tract disease. Contractions of the gallbladder or biliary smooth muscle could precipitate complicat ions includi ngchol ecystitis, cholangitis, andbiliary obstruction.
Pilocarpine may increase ureteral smooth muscle tone and could theoretically precipitate renal colic (or "ureteral reflux"), particularly in patients with nephrolithiasi s.
Cholinergic agonists may have dose-related cent ral nervous system effects. This shoul d beconsi dered whentreatingpat ients with underl ying cogni tive or psychiatric disturbances. intera cti on with the appropriate rece ptor, ch olinergic stimulation (parasympathetic) via a Ca' <-mediated second messen ger sys tem cau ses sa liva produ ction in both the parotid and subma ndibular glands and enzymatic secretion in the parotid glands . Beta-adrenergic stimulation, via cyclic AMP second messen ger sys tems, increases cellul ar metabolism and enzymatic secretions. In the submandibular glands, betaadrenerg ic production ha s the add ed ben efit of increasin g mucin production. Both second messenger systems interact down stre am with effector substa nces that help to bring about the ob served effects. In addition, a host of metabolically act ive compounds has been implicated in the normal phy siologic function of the salivary glands. Epidermal growth factor, nerv e growth factor, renin , and kallikreins have been found in the salivary gland s of many mammalian species, and they might be implicated as playing a role in maintaining normal salivary gland homeostasis.
Saliva typically has a varied co mposition, which is dyn amically altered in respon se to the complex interaction of many of the stimuli ment ioned abo ve. Saliva from the submandibular gland s is prim aril y mucin ous, whereas the parotid glands produ ce a prim aril y serous secretion. In a 24-h our period , most saliva appears to emanate from the parotid and submandibular glands. Th e sublingual gland s make a minor contribution in terms of volume, but a majo r contribution in term s of viscosity . Th e final product is made up of macromolecul e protein s (e.g ., amylase , lysozyme, carbonic anhydrase, and secretory immunoglobulin A), various ion s that influence the normal physiologic pH in the range of 5.4 to 7 (e.g., Na", K+, 1-, Cl, H 2C03 -, and Ca"), and water.
Th e secretory functions of the acinar cells involve the production, storage, and concentration and release of secretory proteins via exocytosis (i.e. , the fusion of the sec retory granule membrane with the plasma membrane and the relea se of its contents). During this process, the sec retory proteins are subjected to exten sive modification by various intracellular organelles (e.g., the rough endoplasmi c reticulum and Gol gi' s apparatus) . Stimulated gland s produce secre tions at a rate of approx imately 0.5 to 1.0 ml/min/g of glandular tissue; a total volume of I to 1.5 L is produced in a 24-ho ur period . Flow rate s are highest dur ing meals as the glands respond to cog nitive, neuronal, and physic al stimuli.
Sodium/iodide symporter. In thyroid cells, iodide uptake occurs acro ss the basol ateral membrane and is dri ven by an inwa rdly directed Na" gradient in an active tran sport process.' Th e sodium/iodide sympor ter involved in the concentration of iodide in the thyro id gland has been sequenced and cloned.P The same receptor has been found to exi st in saliv ary glands, gastric cells, and other extrathyroidal tissues. In salivary glands, the expression seems to be most prevalent in the duct al cells, not the Volume 79, Number 6 acinar cells, according to immunoh istochemical analysis ." Th e sodium/iodide sy mporter outside the thyroid gland, however, doe s not appear to be affected by thyroidstimulating hormone, eve n though the sequence appea rs identica l to that of the thyroid rece ptor on Northern blot analys is and DNA sequencing analysis.' Th e differenti al respon sivene ss to stimulation by thyroid-stimulating hormone might be a result of post-t ran slational modi ficati on of the receptor at various sites. A recent finding that ha s clinical implications is that antibodies to the receptor have been discovered in the ser a of patient s with autoimmune thyroid disease." It has been sugges ted that these same antibodies might have a role in the pathogenesis of autoimmune-mediated salivary gland disea ses such as Sj ogren' s syndrome, although no direct investigations have studied this popul ation.
Radioactive iodine in thyroid disease
It was estimated that 17,200 new cases of thyroid cancer-and 1,200 death s-occurred in the United Stat es in 199 8, representing 1.4% of all new ca nce r cases overall. 9 Most patient s with thyroid ca nce r have well-differe ntiated carcinomas, eith er of papill ary or follicular origin. Th e prim ary treatment of cli nica lly appare nt disease is surge ry ; the degree of resect ion depends on the histology and the extent of the disea se.
In our view, postoperati ve managem ent should con sist of whole-body scanning with either radi oiodine 123 or 131 (1 23 1or 131 1) for the detecti on of met astatic or residual disease, and it should be foll owed by ablation therapy with 1311. The dose admini ster ed for abl ative therapy typically ranges from 30 to 150 mCi , although there is some debate in the literature over the appropriate amount.
Several recent reviews address the role of radioactive iodine in the treatment of thyroid disea ses, and the reader is referred to them for mor e in-depth detail.'?"
Salivary gland dysfunction
Uptake of radioactive iodine by normal tissues. It has been known for many years that irradi ation causes sa livary gland dysfunction . Thi s has impo rtant implication s in the pathogenesis of intra oral disease in patients with head or neck ca ncer. Typi cally, irradi ati on of the head and neck can result in a loss of saliva ry gland function in abo ut 50 to 80% of patients in a dose-dependent mann er. Doses in excess of 50 Gy cause irreversible dam age to sa livary tissue. Bec ause it has been estimated that 40 ,000 patients per year receive irradi ation to the sa livary gland area (from either external-beam sources, intern al sources , or 131 1), this pre sents a potentially serious problem.12 Radi ation damage can lead to muco siti s, a loss of taste acuity, an increase in dent al caries, and alterations in nutritional status. The primary damage is to acinar and ductal cell s, and it can alter ion , mucous, and serous secretions-that is, the number of sodi um and chloride ions is increased and the amo unt of bicarbo nate and sero us sec retions is decreased.
Th e impact of radioactive iodine on salivary gland tiss ue has been known for more than 40 years. Xeros tomia, an increase in de ntal caries, sialade nitis, and taste disturbances are recognized co mplica tions of radioactive iodine therapy.P:" Pros taglandins, whic h have been implica ted in stim ulating salivary gland function, have been found to be decreased in patients who receive 131 1 treatment for thyroid ca ncer and hyperthyroidism. IS It has been sugges ted that beni gn thyroid disease states such as hyperthyroidism can influence the co mpos ition and flow of saliva, although the exac t mechanism is unknown."
As in the thyroid gland, iodide co nce ntra tions in salivary glands can reach 30 to 40 times that see n in plasma. Salivary gland uptake can occur to such a deg ree that it can show up on a scan as uptake and be con fused with meta static thyroid disease .'? Salivary gland flow is decreased in a dose-related manner in patients who have rece ive d radioactive iodine. Malpa ni et al studied the effec ts of 99m Tc0 4 -uptake and excretion in respo nse to sialagogue stim ulation in 33 thyroid cancer patients who received radioactive iodine (range : 1.369 to 38.702 GBq [37 to 1,046 mC i]; mean: 10.16 ±7.659 GBq [274 .594 ± 207 mCi]) and in 14 athyrotic patient s.IS More than 70% of the thyroid ca ncer patient s expe rie nced an abnormal upt ake and exc retion 0[99mTc 0 4 -. Th ere was also a dosedepend ent dec rease in uptake in res ponse to sialagog ue stimulation with higher doses of radio iodine, which affec ted the parot id glands more than it did the submandibular glands. Mi ld parenchymal dysfunctio n can require quant itati ve analysis, and it can be diffic ult to assess by func tional 99mTc-pertechnetate sca nning ."
Asi de fro m these short -and long-term functional effec ts, there is also a theoretical conce rn about the deve lop ment of salivary gland neopl asms after radioac tive iodine thera py. Prevailing data see m to suggest that the incidence of salivary gland neoplasms after radioio dine therapy is low. 2o . 2 1 Few reports have been cite d in the literature of salivary gland neoplasm s that occ urred after radio iodine therapy." Given the sma ll number of patients who receive radioactive iodine therapy, proving a causal relationship between the administration of therapy and the develop ment of malignancy wo uld require a large, pros pec tive , multice nter study.
Assess ment ofdysfunction. In assessing salivary gland dysfunction, it is important to qua ntify patients' subjective co mplaints of xerostomia. The 99m Tc-pertechnetate is taken up and excreted by salivary gland tissue, and it has been used to evaluate salivary gland function. Spiegel et al used 99mTc-pertechnetate to quantify salivary flow befo re and after cu mulative dose s of 170 to 270 mCi of 131 cancer. " Pertechnetate uptake was measured before and after salivary gland stimulation with 2 ml of lemon juice. The authors reported a dose-dependent decrease in salivary gland function, as parotid gland function was reduced by 40 % after doses of 270 mCi. In studying parotid gland function after 131 1 therapy, Maier and Bihl measured stimulated salivary flow rates in a Stenson's duct stent before and I week after treatment with 131J. 24 Levels of sodium, total protein, and alpha amylase activity were measured with standard techniques. There were three study groups: 16 patients received the first-time dose, which was 70 mCi; 14 patients received their second dose , which was 100 mCi; and six patients received the third dose , which was also 100 mCi and which raised their cumulative dose over the three sessions to 270 mCi. The pretherapeutic flow rates were significantly higher in the first group than in the third group (p<0.00 I) . The authors found that both the protein and sodium concentrations increased significantly in all three groups , but alpha amyla se activity increased significantly only in the second and third groups. Three patients developed acute parotitis (one in the second group and two in the third), but parotid flow did not fall below normal in any group. The authors speculated that the ion and protein alterations were secondary to damage to the intraglandular vasculature. Similar alterations have been reported after external-beam radiation in head and neck patients." It might be this type of alteration in saliva composition that accounts for the side effects of radiation therapy. Markers of parotid gland inflammation were also elevated, but the clinical significance of this has yet to be determined.
Complications. Immediate side effects after radioactive iodine are fairly common. Most, however, tend to be short lived, and there are usually no permanent sequelae. Studies have shown that the incidence of salivary gland dysfunction might be as high as 30% in patients who receive 131 1in cumulative doses as high as 300 mCi and 50 to 60% in those who receive it in the area of 500 mCi. 26 Almost all patients who receive 1 Ci or more experience some form of dysfunction." Khan et al reported the onset of sialadenitis and xerostomia in 34 and 18% of patients, respectively; 50% also experienced nausea. " Therefore, even though initial side effects are common after radioactive iodine therapy , from an otolaryngologic perspective it is more relevant to consider the therapy's long-lasting effects.
Caries. Increases in the number of dental caries have been described in patients who have undergone radioactive iodine therapy ." This onset of caries is believed to be secondary to radiation-induced xerostomia, which predisposes to an overgrowth of cariogenic flora. Nevertheless, dental complications do not occur nearly as often after radioactive iodine therapy as they do after externalbeam radiation to the head and neck. Laupa et al found that Volume 79, Number 6
For more information Circle 116 on Reader Service Card NEWKIRK , RINGEL, WARTOFSKY, BURMAN stimulated salivary flow rates were 25.6 and 28.9% lower in male and female cancer patients, respecti vely , than they were in noncancer controls." They also reported that levels of cariogenic Streptococcus mutans were not significantly different in head and neck cancer patients , nor was there a significant inciden ce of dental caries. In fact, the incidence of denta l caries doe s not appear to be higher in thyroid cancer patients who receiv e 131 1 therap y than it is in the general population. Thi s might be attributable to the cont ribution of the submandibular and sublingual glands to saliv a composition , because these glands appea r to be less affected by radioiodine therap y.
Xerostomia . The pred isposing factor in the development of oral complications following radioiodine therapy is belie ved to be the decrease in salivary flow that lead s to xerostomia. In the ir study of patients who had received 131 1 therapy for thyroid cancer, Allw eiss et al found that 10 of 87 patients (11.5 %) had exper ienced salivary gland dysfunction after a median dose of 100 mCi. 30 Nine of the IO patient s had received between 40 and 280 mCi before the precipitating dose. Symptoms includ ed recurrent salivary gland tenderness (nine patients), salivary gland swelling (nine patient s), dry mouth (three patient s), and bitter taste (three patients). The parotid glands were involved most often , followed by the submandibular glands . The authors reported that the mean duration of symptoms was 2 year s for symptoms that had begun as early as I week following therap y.Three patients required antibiotics for suppurative sialadenitis, and one patient required a parotidectomy for intractable pain. Four patients had received external-bea m head and neck radiation, but the dos age was unknown. Salivary gland function was not assessed in these pat ient s.
Temporal dysfunction/ta ste disturbance. Salivary gland dysfunction has been found to occur in pati ents even after low-dose therapy . Patients usually experience tran sient side effects during the immedi ate post-treatment period , but sometimes long-term side effect s are encountered. Lin et al studied 56 patient s with well-different iated thyroid cancer who received 40 mCi of 131 1 after whol ebody sca nning with 2 mCi of 131J.31Patient s were examined for signs and symptoms of salivary gland dysfunction before treatment and on days 2 and 7 after treatment. The most common side effects were xerostomia and nausea , which occurred in about 5% of patients. Most symptoms began within 24 to 48 hour s and, except for the xerostomia, resolv ed within 1 week of therapy; one patient experienced parotid gland tend erness, and one patient had submandibular gland tend erne ss.
Alexander et al interview ed 203 patients who were being followed for well-differentiated thyroid carcinoma." Patients were advised to increase their fluid and secretagogue intake prior to therapy, and those who could tolerate it were given pilocarpine. Patients were assigned to 464 one of five groups, depending on the cumulative dosage of radioiodine they had received : 134 mCi or less (n=38); 135 to269 mCi (n=7 I); 270to499 mCi (n=53); 500 to 999 mCi (n=24 ), and I Ci or more (n= 17). The duration of compl aints was classified as either intermediat e (from discharge to 3 mo) or long term (>3 mo). One-third of these patient s (67/203) reported intermediate sialadenitis; the parotid gland s were invol ved in 8 I% of these cases (54/67) and the submandibular glands in 46 % (31/67) . Bilateral involv ement occurred in the parotid gland s in 60% (40/67) and in the submandibular glands in 74 % (23/ 3 I) . Taste disturb ance was reported by 27% of the patients (551203), but it returned to normal within 12 weeks . Almost 43 % of patient s (871203) repo rted dry mouth , but complete xerostomia-defined as the inability to swallow food without simultaneously drinking water-was reported by only 4.4 % (9/203). Symptoms appeared to be dose dependent. It is intere sting that the patients who were given pilocarpin e experienced no signi ficant decre ase in dysfunction .
Van Nostrand et al described a method ofestimating the maximum safe dose of radioiodine by calculating the average beta dose administered to the blood per mCiday ." Their dose estimation s were based on the total number of sessions (15) that their 10 patients underwent. Symptoms or sign s of salivary gland dysfunction occurred during 10 of 15 therapy sess ions. Pain occurred in six; tenderness in three ; swelling in three; and bitter taste, loss of taste, or dry mouth in five . Only one case of dry mouth persisted beyond three sessions, and it eventually resol ved without further intervention. During 60% of the therapy sess ions (9/15 ), salivary gland side effects occurred while patient s were in the hospital ; following 20% of these session s (3/15), symptoms still persi sted at 3 month s. It is interestin g that taste disturbances occurred after the administration of doses ranging from 230 to 450 mCi and in patients who had previously receiv ed doses of at least 100 mCi (range: 100 to 664 mCi). Thi s indic ates that large doses of isotope might be nece ssary before taste is noticeabl y affected.
Cancer risk. One of the major concerns about radioiodine is that it can place patients at risk for secondary malignancies. At particular risk are organ s that concentrate 1311-namely , the salivary glands, the digestive tract , and the bladder." Hall et al examined the records of 1,955 thyroid cancer patients in the Swedish cancer registry between 1950 and 1975. 20 Of this gro up, 834 patients (43%) received 131Itherapy (group 1), while the rem aining I, 121 patients did not (group 2). The two groups were comparable in term s of mean age and gender distribution. Neck irradiation was administered to 36 and 37% of groups I and 2, respectively, and whole-body irradi ation was admini stered to 16 and 6%, respectively. The mean total dose of 131 1 was 123 mCi (range : 13 to 1,360 patients who were irrad iated wi th 131 1, 78 % rec eived it to ablate the thyroid and 22% for the treatm ent of distant metastases. Sevent y-eight percent of the patients rec eived on ly one do se . Th e estim ated radiatio n do ses to the sal ivary gla nds, sto mac h, small intestine, and bladder were 1.9,2.1, 1.4 , and 2. 1 Gy , re spe ctivel y. Papill ary can cers were present in 54 % of gro up I and 61 % of gro up 2, and follicular ca nce rs were present in 31 and 15%, re spectivel y. Th e mean peri od until the de velopment of a second malignancy was I I years in the 131 1 gro up and 12 years in the other group. In term s of secondary cancers, group I ha d a higher-than -e xpected incidence of salivary gland, kidney , fem ale genital, and adre nal gla nd mal ignancies. In gro up 2, a high er-th an-expected incidence wa s seen onl y in the adrena l gla nds. Org an s that received mo re than 1.0 G y (sa livar y glands, stoma ch, sma ll int estine, and bl add er) had high er-than-expected ca nce r rates. Edmonds and Smith reviewed the histories of 241 patients wh o had rec eive d radioiodine therapy for thy roid cancer (mean follow up: 11.2 yr) ." Th e radiatio n do se to be deli vered to selec ted organ s was estima ted on the basis of the amount of 13 1 1in the normal thyroid tissu e , tumorous thy roid tissue, and other tissues. Ten percent of the se patients exper ience d pain in one of the saliva ry gla nds, bu t non e dev eloped a mali gn an cy there, and there were no 1 ---; : : =====================: . . . . . . . , serio us side effects. Three patients did develop nodules, but their etiology wa s not di sclosed . The authors noted that the se pat ient s did hav e a slightly high er risk of bl add er cancer and leukemi a.
M ore rec ently, Ron et al retrospectively revi ewed the ex pe rience of more than 35,000 patients who had been followed for hy perthyroidism ." Some 91 % of these patients had Grav es' di sease, and 65 % were treated with 131 1 (me an do se: 6.1 mCi per treatment; mean number of treatments : 1.8). Rad ioacti ve iodine was not linked to the incidence of tot al ca ncer mo rtalit y or to the inci den ce of any specific ca nce r other than thyroid cancer. It mu st be noted that salivary gland mali gnancy wa s not noted in thi s population. Thi s is in contrast to the findings of Ho ffm an et al, who found an increased risk of saliva ry gland mali gn anci es in hyperthyroid pati ents who were treated with radioiod ine therapy." Overall , however, based on these stud ies , it appears that radioa ctive iodine do es not de fin itivel y contribute to the development of subse quent saliv ary gla nd neoplasia, despite the high do ses that these tissues rec ei ve. tion exposure to the tissues." He reported a progressive loss of salivary gland function with increa sing doses of J3JI,even as long as 6 month s after therap y. Hydration and sialagogues are a reasonable treatment option for preventing radiation-induced sialadenitis. However, even with proper precautions, patients still experience side effects, so new strategies oug ht to be investigated. Cytoprotective agents. Ongoing work on the prevention of the salivary gland complications of radioactive iodine therapy has focused on agents that protect salivary gland cells without compromising therapeutic efficacy . Severa l options have been explored , including the use of substa nces that inhibit catecho lamine uptake and metabolism? and the use of cholinergic preparations such as pilocarp ine." Zinc-containing compounds (e.g., zincdesferrioxamine) have also been credited with reduc ing the damaging effects of radiation -induced salivary gland dysfunction in anima l model s, presumably by acting as free-radical scavengers." Again, further investigations into these areas are required.
Another promising compound is the aminothiol amifostine (WR-272 I), developed during the Cold War as part of the military ' s search for an agent that would protect personnel in case of a nuclear attack .":" Amifostine is a prodrug that is metabolized into its active form by desphosphorylation of the compound by membrane-bound alkaline phosphatases. The active compound (WR-I 065) is taken up into cells and is believed to be responsi ble for the cytoprotective effect again st both radiation and chemotherapeutic co mpounds. In anima l models, the compound is differentially taken up by norma l cells rather than by tumor ce lls: One of its mechanisms of action is believed to be the scavengi ng of free radicals through its free thiol group." The efficacy of this compound in reducing radiation-and drug-induced toxicities while not interfering with their antitumor activity has been proven in numerous preclinical studies on various cell lines, including head, neck, and salivary gland tissue . The use of amifostine might be most appropriate in the setting of external-beam radiation, where the local tissue is at a much higher risk of complications such as mucositis, which can be devastating during and after treatment.
Typically, patients who receive radiation doses in excess of 50 Gy are at high risk for comp lications . Buntzel et al conducted a phase II study of 39 patient s with advanced head and neck cancer who received a combination of fractionated radiotherapy and simultaneous carboplatin chemotherapy (total dose : 60 Gy).43Twentyfive patient s were randomized to receive a 500-mg infusion of amifostine IS minutes prior to chemotherapy dosing. None of the amifostine patien ts experienced grade III or IV mucosi tis, while 12 of the 14 contro ls did. In additio n, the incidence of xerostomia, leukopenia, and thrombocytopenia was significantly lower in the ami- 44 Amifostine also has potential for patients who undergo radi oactive iod ine therapy, particularly those who receive multiple treatments and cumulati ve doses greater than 500 mCi. Amifostine sho ws a greater amount of uptake in norm al sali vary gland tissue than in normal thyro id tissue." Bohu slavizki et al prospective ly evaluated salivary gland function in 50 patients who had well-differentiated thyroid cancer." In this group, 21 patients recei ved 3 GBg (8 I. I mCi) and 29 patients received 6 GBg ( 162.2 mCi) as their seco nd treatment (which was administered 6'months after the ir initial 3-GBg dose) . Patients in both gro ups were randomized to receive eit her IV arnifo stine (500 mg/ rrr') or placebo directly before 131 1 therapy. Quantit ative salivary gland ana lysis was performed with 100 to 120 MBg of 99mTc-pertechnetate. Three months later, both parotid and submandibular gland function were sig nificantly dimini shed in the control group, but not in the amifostin e group. After I year , I I of the 25 controls (44%) developed xero stomi a, compared with none of the 25 amifostine patients. A significant dec rease in mean blood pres sure was noted in the amifostine group, which forc ed a temporary suspension of infusion in two pati ent s. The clinical ben efits see n in this study mirror the findin gs of preclinical studies.
